BICO Group AB (publ) (BICO.ST)
SEK 34.84
(5.07%)
SEK 34.84
(5.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | 322.3 Million SEK | 913.52% |
| 2021 | 31.8 Million SEK | 180.5% |
| 2020 | -39.5 Million SEK | -778.63% |
| 2019 | 5.82 Million SEK | 56.56% |
| 2018 | 3.71 Million SEK | 434.2% |
| 2017 | 696 Thousand SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -583.3 Million SEK | -5061.95% |
| 2023 Q3 | 87.1 Million SEK | 114.93% |
| 2023 Q1 | -11.3 Million SEK | 94.46% |
| 2022 Q3 | 260.2 Million SEK | 46.51% |
| 2022 Q2 | 177.6 Million SEK | 242.86% |
| 2022 Q1 | 51.8 Million SEK | -38.11% |
| 2022 FY | - SEK | 913.52% |
| 2022 Q4 | -203.9 Million SEK | -178.36% |
| 2021 FY | - SEK | 180.5% |
| 2021 Q2 | 16.1 Million SEK | 163.89% |
| 2021 Q3 | -27.5 Million SEK | -270.81% |
| 2021 Q4 | 83.7 Million SEK | 404.36% |
| 2021 Q1 | -25.2 Million SEK | 0.0% |
| 2020 Q1 | -13.75 Million SEK | -2059.34% |
| 2020 FY | - SEK | -778.63% |
| 2020 Q2 | -10.53 Million SEK | 23.38% |
| 2020 Q3 | -6.08 Million SEK | 42.23% |
| 2019 Q1 | 3.01 Million SEK | 89.28% |
| 2019 FY | - SEK | 56.56% |
| 2019 Q2 | 2.05 Million SEK | -31.8% |
| 2019 Q4 | -637 Thousand SEK | -209.45% |
| 2019 Q3 | 582 Thousand SEK | -71.73% |
| 2018 Q4 | 1.59 Million SEK | 25.0% |
| 2018 FY | - SEK | 434.2% |
| 2018 Q1 | 1.42 Million SEK | 429.26% |
| 2018 Q2 | 1.27 Million SEK | -10.85% |
| 2018 Q3 | 1.27 Million SEK | 0.16% |
| 2017 Q2 | -433 Thousand SEK | -331.55% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | 187 Thousand SEK | -63.73% |
| 2017 Q4 | 270 Thousand SEK | -39.46% |
| 2017 Q3 | 446 Thousand SEK | 203.0% |
| 2016 Q4 | 515.56 Thousand SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 517.909% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 21.753% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 21.753% |
| Arcoma AB | 6.24 Million SEK | -5058.451% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 458.183% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | -388.489% |
| CellaVision AB (publ) | 207.24 Million SEK | -55.516% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 571.158% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 1253.42% |
| C-Rad AB (publ) | 48.9 Million SEK | -559.046% |
| Duearity AB (publ) | -24.77 Million SEK | 1400.698% |
| Dignitana AB (publ) | -264 Thousand SEK | 122183.333% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 467.503% |
| Getinge AB (publ) | 5.92 Billion SEK | 94.564% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 579.256% |
| Iconovo AB (publ) | -35.33 Million SEK | 1012.115% |
| Integrum AB (publ) | 8.76 Million SEK | -3578.582% |
| Luxbright AB (publ) | -23.86 Million SEK | 1450.415% |
| Mentice AB (publ) | 28.87 Million SEK | -1016.268% |
| OssDsign AB (publ) | -122.02 Million SEK | 364.135% |
| Paxman AB (publ) | 31.22 Million SEK | -932.054% |
| Promimic AB (publ) | -3.68 Million SEK | 8848.645% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 314.146% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 721.853% |
| ScandiDos AB (publ) | -13.35 Million SEK | 2513.148% |
| Sectra AB (publ) | 615.06 Million SEK | 47.599% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 723.718% |
| Senzime AB (publ) | -118.82 Million SEK | 371.244% |
| SpectraCure AB (publ) | -20.96 Million SEK | 1637.031% |
| Stille AB | 56.04 Million SEK | -475.115% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 110.119% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | -154.634% |